Citations

Clear

16280 citation(s) found for "Yu, David".

Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program
Yarur, Andrés , Chiorean, Michael , Allegretti, Jessica R. , Cross, Raymond, Ha, Christina , Goetsch, Martina, McDonnell, Aoibhinn , Dalam, Alexis B, Wu, Joseph , Blanco, David, Abbatemarco, Arcangelo M. , Yarur, Andres J , Ha, Christina , Blanco, David A, Panés, Julián

Mayo Clinic

Inflammatory Bowel Diseases | December 13, 2024 | Volume: 31 | Issue: 8 | Pages: 2144-2153

10.1093/ibd/izae288 | PMID 39671695 Get It

Abstract Background Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). We assessed the benefit of etrasimod monotherapy and the impact of concomitant corticosteroids (CS) and/or 5-aminosalicylates (5-ASA) therapy. Methods In ELEVATE UC 52 and ELEVATE UC 12, patients with moderately to severely active UC were randomized 2:1 to etrasimod 2 mg QD or placebo for 52 and 12 weeks, respectively. Oral CS or 5-ASA were allowed at baseline. Patients in the monotherapy subgroup received etrasimod or placebo without concomitant CS and/or 5-ASA at baseline. Predefined primary (clinical remission) and key secondary efficacy endpoints aligned with those from both trials and were assessed at Week 12 and Week 52. Safety was assessed up to Week 52. Results Clinical remission rates at Weeks 12 and 52 were significantly higher for etrasimod compared with placebo in patients receiving monotherapy (Week 12: 26.2% vs 4.8%; Week 52: 35.7% vs 4.0%). Differences vs placebo were statistically significant for all predefined endpoints at both time points in patients receiving monotherapy or etrasimod with concomitant 5-ASA only (all P < .05); numerical differences, due to small sample sizes, vs placebo were observed for all endpoints in the CS only and CS + 5-ASA subgroups. Safety was consistent with the overall population. Conclusions Etrasimod monotherapy showed consistent efficacy and safety vs placebo; no apparent benefit was observed with concomitant CS and/or 5-ASA in patients receiving etrasimod. Clinical trial registration NCT03945188; NCT03996369.
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone
Lary, Christine W. , Atkinson, Elizabeth J. , Nayema, Zannatun, Roy, Tyler, Peters, Rebecca , Scott, Griffin T, Chen, Hongyu , Nagarajan, Archana , Brown, Aaron, Motyl, Katherine J. , Monroe, David G , Spillane, Jennifer, Scott, Griffin T, Brown, Aaron, Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | December 13, 2024 | Volume: 40 | Issue: 2 | Pages: 231-240

10.1093/jbmr/zjae200 | PMID 39673185 Get It

Abstract Motivated by studies showing an association between beta blocker (BB) use and positive bone outcomes, a pilot randomized control trial was performed at the Mayo Clinic which randomized postmenopausal women to placebo, propranolol (40 or 80 mg twice daily), atenolol (50 mg/d), or nebivolol (5 mg/d) to determine changes in bone turnover markers (BTMs) and in BMD over 20 wk. Pharmacogenetic effects and microRNA-mediated mechanisms involving beta adrenergic receptor and related genes have previously been found. We sought to validate these effects and discover new candidates in an ancillary study to the pilot clinical trial. We genotyped all participants and performed microRNA (miRNA) sequencing at baseline and at 20 wk for 24 participants from the atenolol or placebo groups. We discovered several variants in ADRB1, ADRB2, and HDAC4 which showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs. Our miRNA results showed a significant treatment effect for miR-19a-3p over time with atenolol use in the low-responder group compared to placebo. Overall, the longitudinal miRNA analysis showed a large number of miRNAs which were up-regulated over the trial in the low responders but not the high responders compared to placebo, of which miR-19a-3p was one example. Finally, we compared the response to atenolol treatment for cardiovascular traits (pulse and blood pressure) with the response for the bone resorption marker, C-terminal telopeptide, and found a largely independent effect. Our results have implications for personalized therapy and for understanding mechanisms of BB treatment effect on bone.
Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer
Huang, Chen , Srinivasan, Ramakrishnan Rajaram , Lewis, Alaina , Sallas, Christina , Zhao, Na , Cao, Jin , Pilcher, Jacob B., Moon, Chang In, Liao, Yuxing , Rimawi, Mothaffar F. , Malovannaya, Anna , Li, Shunqiang , Kraushaar, Daniel C. , Goetz, Matthew P., Boughey, JC , Wang, Liewei, Kalari, Krishna R., Suman, Vera J., Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, F, Welm, Bryan E. , Welm, Alana L. , Zhang, Bing , Lei, Jonathan T , Zhao, Na , Wen, Bo , Rimawi, Mothaffar , Lei, Jonathan T. , Dobrolecki, Lacey E. , Vasaikar, Suhas , Landua, John David , Pilcher, Jacob B. , Hilsenbeck, Susan Galloway , Ellis, Matthew J. , Petrosyan, Varduhi, Li, Kai shang , Saltzman, Alexander B. , Jain, Antrix , Wulf, Gerburg M. , Marangoni, Elisabetta , Wang, Tao , Goetz, Matthew P. , Damodaran, Senthil , Zheng, Xiaofeng , Meric‐Bernstam, Funda , Echeverria, Gloria Vittone , Anurag, Meenakshi , Chen, Xi , Lewis, Michael T.

Mayo Clinic

No container title available | December 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.12.09.627518 | PMID 39713418 Get It

Abstract Chemotherapy regimens for triple-negative breast cancer (TNBC) combine agents without knowing which agents drive response. Consequently, predictors derived from multi-agent regimens cannot be assumed to generalize to individual drugs or other regimens, motivating development of treatment-matched predictors. Here, we used TNBC patient-derived xenografts (PDXs) treated with carboplatin, docetaxel, or the combination to deconvolute drug-specific responses and identify associated molecular features. Combination treatment rarely improved upon the best single agent, with enhanced responses in only 13% of PDXs and antagonism in a comparable fraction. Proteogenomic analyses identified high cytokeratin-5 (KRT5) as a general marker of chemotherapy responsiveness and KRT5 immunohistochemistry discriminated responsive PDXs (AUROC, 0.83). To train treatment-specific predictors, we integrated these data with independent PDX and clinical cohorts with responses assessed after anthracycline-free platinum, taxane, or platinum-taxane therapy, ensuring response corresponded to the modeled treatment. Four feature selection strategies yielded largely nonoverlapping biomarker panels converging on treatment-relevant pathways. On independent test data, RNA-based predictors of complete response (CR) to platinum-based (carboplatin or cisplatin) and taxane-based (docetaxel or paclitaxel) chemotherapy achieved AUROCs of 0.80 and 0.86, respectively. For platinum-taxane regimens (carboplatin plus docetaxel or paclitaxel), proteomic-guided feature selection generated a 10-biomarker, protein- informed RNA predictor of pathologic complete response (pCR) that outperformed RNA-only feature selection and achieved an AUROC of 0.85 in an independent clinical cohort, while retaining practicality as an RNA-based assay. Treatment-matched integration of multi-omic PDX and clinical datasets provides a framework for chemotherapy-specific predictors with clinically relevant performance, supporting biomarker-guided precision selection and treatment optimization for patients with TNBC. Statement of significance Integration of multi-omic data from patient-derived xenografts with treatment-matched clinical cohorts yielded three retrospectively validated predictors of platinum, taxane, and platinum+taxane response, enabling biomarker-guided chemotherapy selection for patients with triple-negative breast cancer.
Making Sense of ‘Porto‐Sinusoidal Vascular Disorder’: What Does It Mean for the Pathologist and the Patient?
Gouw, Annette S.H. , Callea, Francesco , Dienes, Hans‐Peter, Goodman, Zachary , Kakar, Sanjay , Kleiner, David E. , Lackner, Carolin , Park, Young Nyun , Roberts, Eve A., Schirmacher, Peter , Terracciano, Luigi , Wanless, Ian R., Zen, Yoh , Kleiner, David Erwin , Park, Young Nyun , Tiniakos, Dina , Zen, Yoh , Burt, Alastair D , Clouston, Andrew Donald , Kakar, Sanjay , Torbenson, Michael , Weber, Achim

Mayo Clinic

Liver International | December 12, 2024 | Volume: 45 | Issue: 1 | Pages: No page available

10.1111/liv.16196 | PMID 39665793 Get It

Pseudo-HFOs Elimination in iEEG Recordings Using a Robust Residual-Based Dictionary Learning Framework
Besheli, Behrang Fazli , Sha, Zhiyi , Ayyoubi, Amir Hossein , Swamy, Chandra Prakash , Henry, Thomas R. , Miller, Kai J. , Parker, Jonathon J. , Darrow, David , Ince, Nuri F. , Fazli Besheli, Behrang , Worrell, Gregory A.

Mayo Clinic

IEEE Journal of Biomedical and Health Informatics | December 12, 2024 | Volume: 29 | Issue: 2 | Pages: 857-869

10.1109/jbhi.2024.3516613 | PMID 40030514 Get It

Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Antonelli, Luca , Heidenreich, Axel , Baky, Fady , Branger, Nicolas , Daneshmand, Siamak , Djaladat, Hooman , Eggener, Scott E. , Sexton, Wade J. , Nicol, David , Olson, Kathleen, Paffenholz, Pia , Porter, James , Qian, Zhiyu , Rocco, Nicholas R., Stroup, Sean P. , Tachibana, Isamu , Cary, Clint , Daneshmand, Siamak , Djaladat, Hooman , Ghoreifi, Alireza , Nicol, David , Nicolai, Nicola , Paffenholz, Pia , Porter, James , Stroup, Sean P , Fankhauser, Christian Daniel , Bagrodia, Aditya , Amini, Armon , Cazzaniga, Walter , Clinton, Timothy Nguyen , Ghoreifi, Alireza , Hamilton, Robert J , Ho, Matthew, Nazzani, Sebastiano , Olson, Kathleen, Yerrapragada, Anirudh , Terbuch, Angelika , Singla, Nirmish

Mayo Clinic

BJU International | December 11, 2024 | Volume: 135 | Issue: 4 | Pages: 621-628

10.1111/bju.16618 | PMID 39662898 Get It

Objectives To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker‐negative non‐seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications. Materials and Methods Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease‐free survival (DFS). Results A larger retroperitoneal lymph node diameter was associated with pure teratoma in the RPLND specimen (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01–1.07; P = 0.03), but no association was observed with DFS. The 5‐year DFS rates in marker negative CS 2a and 2b were 79% and 76%. In men with non‐teratomatous viable cancer in the RPLND specimen, the 5‐year DFS rates for CS 2a and 2b were 95% and 87% with adjuvant chemotherapy, and 67% and 74% without adjuvant chemotherapy. We did not identify an association between the number of adjuvant chemotherapy cycles and DFS. Conclusions Our study suggests considering primary RPLND not only in marker‐negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker‐positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
McCord, Matthew , Sears, Thomas , An, Shejuan, James, C. David , Ruggeri, Bruce , Gueble, Susan , Bindra, Ranjit S. , Horbinski, Craig , Sarkaria, Jann, Bindra, Ranjit , Horbinski, Craig , Sears, Thomas , McCord, Matthew , Wang, Wenxia, Chaliparambil, Rahul Kishore , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | December 11, 2024 | Volume: 27 | Issue: 3 | Pages: 644-651

10.1093/neuonc/noae257 | PMID 39658092 Get It

Abstract Background Acquired resistance to temozolomide (TMZ) chemotherapy due to DNA mismatch repair (MMR) enzyme deficiency is a barrier to improving outcomes for isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients. KL-50 is a new imidazotetrazine-based therapeutic designed to induce DNA interstrand cross-links, and subsequent double-stranded breaks, in an MMR-independent manner in cells with O-6-methylguanine-DNA methyltransferase (MGMT) deficiency. Previous research showed its efficacy against LN229 glioma cells with MMR and MGMT knockdown. Its activity against patient-derived GBM that model post-TMZ recurrent tumors is unclear. Methods We created MMR-deficient GBM patient-derived xenografts through exposure to TMZ, followed by treatment with additional TMZ or KL-50. We also generated isogenic, MSH6 knockout (KO) patient-derived GBM and tested them for sensitivity to TMZ and KL-50. Results KL-50 extended the median survival of mice intracranially engrafted with either patient-derived TMZ-naïve GBM6 or TMZ-naïve GBM12 by 1.75-fold and 2.15-fold, respectively (P < 0.0001). A low dose (4 Gy) of fractionated RT further extended the survival of KL-50-treated GBM12 mice (median survival = 80 days for RT + KL-50 vs. 71 days KL-50 alone, P = 0.018). KL-50 also extended the median survival of mice engrafted with post-TMZ, MMR-deficient GBM6R-m185 (140 days for KL-50 vs. 37 days for vehicle, P < 0.0001). MSH6 KO increased TMZ IC50 for GBM6 and GBM12 cultures by >5-fold and >12-fold for cell death and live cell count outputs, respectively. In contrast, MSH6-KO actually decreased KL-50 IC50 by 10–80%. Conclusion KL-50-based compounds are a promising new strategy for the treatment of MGMT-deficient, MMR-deficient GBM that recurs after frontline TMZ.
Olfactory function is reduced in a subset of former elite American football players with traumatic encephalopathy syndrome
Braunecker, Ben J, Groh, Jenna R., Adler, Charles H. , Alosco, Michael L. , Tripodis, Yorghos , Balcer, Laura J. , Bernick, Charles , Banks, Sarah J. , Wethe, Jennifer V. , Palmisano, Joseph , Martin, Brett, Hartlage, Kaitlin , Geda, Yonas E. , Cummings, Jeffery L., Shenton, Martha E., Reiman, Eric M. , Braunecker, Ben J. , Tripodis, Yorghos , Adler, C H , Geda, Yonas E , Wethe, Jennifer V , Braunecker, Ben J. , Groh, Jenna R. , Dodick, David W. , Barr, William , Cantu, Robert C. , Katz, Douglas I. , Mez, Jesse , Shenton, M.E., Stern, Robert A.

Mayo Clinic

Chemical Senses | December 11, 2024 | Volume: 49 | Issue: No issue available | Pages: No page available

10.1093/chemse/bjae043 | PMID 39657828 Get It

Abstract Former American football players are at risk for developing traumatic encephalopathy syndrome (TES), the clinical disorder associated with neuropathologically diagnosed chronic traumatic encephalopathy (CTE). The objective of this study was to determine whether hyposmia is present in traumatic encephalopathy syndrome. The study included 119 former professional American football players, 60 former college football players, and 58 same-age asymptomatic unexposed men from the DIAGNOSE CTE Research Project. All subjects included in the analysis had completed the Brief Smell Identification Test (B-SIT). Traumatic encephalopathy syndrome and the level of CTE certainty were diagnosed using the 2021 NINDS consensus diagnostic criteria. TES is categorized antemortem by provisional levels of increasing CTE certainty: Suggestive, Possible, and Probable. Former players who had traumatic encephalopathy syndrome and Probable CTE had lower B-SIT scores than those with TES and Suggestive CTE. Hyposmia was more likely in the former players with TES who were either CTE Possible or Probable than in those who did not have TES or had TES but were less likely to have CTE, or CTE Suggestive. There was no difference in B-SIT scores between all former players versus unexposed men nor overall between the football players with and without TES. We conclude that lower B-SIT scores may be a clinical biomarker for underlying CTE in former American football players.
(136) A NONINTERVENTIONAL, RETROSPECTIVE MULTICENTER STUDY TO EVALUATE CCH TREATMENT IN ADULT MALE PARTICIPANTS WITH VENTRAL CURVATURE OF THE PENIS DUE TO PEYRONIE’S DISEASE
Ziegelmann, Matthew , Bennett, R, Tursi, Jennifer, Hurley, David , Kaufman, Gregory J., Gumpf, K, Rezakhani, T, Ayad, M, Islam, M, Tatem, Andrew J. , Bennett, R, Andrews, J, Mills, James L.

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.133 Get It

Abstract Introduction Peyronie’s disease (PD) is a connective tissue disorder characterized by the replacement of normal elastic fibers of the tunica albuginea with collagen-containing plaques. This alteration may result in penile deformities that are most evident during erection, which can lead to significant emotional distress, sexual dysfunction, and penile pain. Collagenase clostridium histolyticum (CCH) is indicated for the treatment of adult men with PD with a palpable plaque and curvature deformity of at least 30 degrees at therapy onset. Notably, men with ventral curvature (VC) were not included in the CCH clinical trial program due to potential concerns over the proximity of the urethra to the site of injection. Currently, CCH is contraindicated in Peyronie’s plaques that involve the penile urethra. Urethral involvement of a PD plaque is rare due to the anatomy of those structures. PD plaques form in the tunica albuginea as opposed to the corpus spongiosum which directly surrounds the urethra. Also, multiple prospective and retrospective studies have documented favorable outcomes using CCH for PD with VC. Thus, CCH may be a reasonable treatment option for patients suffering with ventral and ventrolateral penile curvatures in the absence of direct urethral involvement. Objective We are conducting a multicenter real-world retrospective collaborative research study of the safety and effectiveness of CCH in the treatment of men who had PD with VC. Methods A Phase 4, multicenter, noninterventional, retrospective review of medical records from approximately 10-15 US physician sites is being conducted. Eligible patients include those ≥18 years old with a PD diagnosis with VC and a palpable plaque that had been treated with CCH from 2014 to the study start date at the site. The primary effectiveness endpoint is percent change from (pretreatment) baseline in degree of VC at the last visit as measured at follow-up within 6 months post-treatment. Secondary endpoints include mean change from Baseline in VC and the proportion of patients with ≥30% improvement from baseline in VC at the last visit during which a measurement was collected within 6 months of final CCH treatment. Adverse events are collected throughout the study period to assess safety. Results In this first look at early data, 32 eligible patients with a median age (range) of 58.0 years (25-75 years) were included in the analysis. The percent change in penile curvature from baseline decreased, representing an improvement of 45.4% (SD: 28.62 [0-100]) (Figure), with 68.8% (22/32) of patients experiencing ≥30% improvement from baseline in VC. There were no serious adverse events. Five patients had at least one treatment-related adverse event (TRAE); 4 TRAEs were mild-to-moderate in severity and 2 were unknown. There were no reports of urethral involvement or injury. TRAEs were related to injection site bruising (n = 3), hemorrhage (n = 1), swelling (n = 1), and muscle spasm (n = 1). Conclusions This first look at early data reflecting improvements in men with PD and VC (data cutoff: 06/14/2024) is consistent with findings of effectiveness and tolerability of CCH in the treatment of men with dorsal and dorsolateral penile curvature. Disclosure Yes, this is sponsored by industry/sponsor: Endo USA Inc. Clarification: Industry initiated, executed and funded study. Any of the authors act as a consultant, employee or shareholder of an industry for: MZ is an investigator and consultant for Endo USA Inc. MI is an investigator for Endo USA Inc. AT is an investigator and consultant for Endo USA Inc. RB is an investigator for Endo USA Inc. JM is an investigator and consultant for Endo USA Inc. JT is an employee of Endo USA Inc. DH is an employee of Endo USA Inc. GK is an employee of Endo USA Inc. KG is an investigator and consultant for Endo USA Inc. JA is an employee of Endo USA Inc. TR is an employee of Endo USA Inc. MA is an employee of Endo USA Inc. JM is an investigator for Endo USA Inc.
(074) OFFICE-BASED MICRODISSECTION TESTICULAR SPERM EXTRACTION FOR NONOBSTRUCTIVE AZOOSPERMIA RESULTS IN HIGH SPERM RETRIEVAL RATES
Seyer, Amanda K., Ainsworth, A.Jerald, Khan, Zaraq , Walker, David , Ainsworth, A, Shenoy, Chandra C. , Babayev, Samir N. , Stewart, Elizabeth A. , Zhao, Y, Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.072 Get It

Abstract Introduction Microdissection testicular sperm extraction (microTESE) is performed in men with nonobstructive azoospermia who desire sperm retrieval for use in IVF. This procedure can be performed in the operating room or in the clinic with local analgesic. Objective To report office-based microTESE sperm retrieval, fertilization, and livebirth rates. Methods A review was conducted of all patients who underwent office-based microTESE for nonobstructive azoospermia with a partner that who underwent concurrent oocyte retrieval for an intended in-vitro fertilization (IVF) intracytoplasmic injection (ICSI) cycle 2022-2024. All male partners underwent Y chromosome microdeletion testing, karyotype analysis, and hormonal testing preoperatively. Patients with a diagnosis of hypogonadism were offered medical therapy and those diagnosed with a varicocele were offered varicocelectomy prior to microTESE. Office-based microTESE was performed using a surgical operating microscope, spermatic cord block, and oral anxiolytic. Female partners underwent oocyte retrieval with oocyte cryopreservation prior to microTESE. Oocyte warming and ICSI was performed only following the collection of motile sperm from the fresh microTESE samples. Relevant demographic and clinical data were collected for patients and their partners. Descriptive data analysis was performed and reported as mean ± standard deviation. Results Ten patients underwent 11 office-based microTESE procedures. One patient had repeat microTESE following an unsuccessful IVF/ICSI cycle. Overall sperm retrieval rate was 70% for first time microTESE with mean search time 197.2 ± 96.5 min. Amongst couples with successful sperm retrieval, normal fertilization rate was 42%. Early cleavage arrest was seen in 84% of normally fertilized oocytes with a 16% blastocyst rate. Embryo development arrested entirely in two couples, while the remaining five couples had at least one blastocyst on day 5 and underwent embryo transfer. Of these, four resulted in a clinical pregnancy (36%). Three couples had a successful live birth and one has an ongoing pregnancy with ultrasound-confirmed fetal heartbeat. Conclusions Our small series demonstrates high sperm retrieval rates from office-based microTESE. Fertilization rates, clinical pregnancies and live birth rates are comparable with those reported in the literature. Given the financial cost associated with microTESE and IVF/ICSI for nonobstructive azoospermia patients, office-based microTESE may be a solution to make the process more financially accessible for couples. Disclosure No.